What was the 3-year target vessel failure (TVF) rate for the Angio group in the ULTIMATE trial?

• A. 10.7%
• B. 6.6%
• C. 9.2%
• D. 4.2%

Answer: (A)

The 3-year target vessel failure (TVF) rate for the Angio group in the ULTIMATE trial is notably significant for understanding the long-term effectiveness and safety of the treatment being assessed. This metric reflects the cumulative incidence of clinical events related to the target vessel, including death, myocardial infarction, and revascularization.

The reported rate of 10.7% indicates that in the Angio group, there was a relative level of target vessel-related complications or failures within three years that is essential for evaluating the overall success of the intervention compared to other treatment modalities. Such percentages help practitioners make informed decisions by weighing the risks and benefits associated with the therapy being analyzed.

In clinical trials, target vessel failure rates are critical benchmarks since they encapsulate the effectiveness of interventions in preventing adverse outcomes in patients. This particular rate serves as a basis for understanding how well the procedure performs in a real-world setting and can guide future treatment protocols.